Current Perspective of Antiviral Strategies against COVID-19
- 2 June 2020
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (7), 1624-1634
- https://doi.org/10.1021/acsinfecdis.0c00236
Abstract
COVID-19 was declared a pandemic by the World Health Organisation on March 11, 2020. This novel coronavirus disease, caused by the SARS-CoV-2 virus, has resulted in severe and unprecedented social and economic disruptions globally. Since the discovery of COVID-19 in December 2019, numerous antivirals have been tested for efficacy against SARS-CoV-2 in vitro and also clinically in order to treat this disease. This review article discusses the main antiviral strategies currently employed and summarizes reported in vitro and in vivo efficacies of key antiviral compounds in use.Keywords
Funding Information
- National Medical Research Council (SOF731)
- Ministry of Education - Singapore (MOE2017 T2-1-078, MOE2017 T2-2-014)
- National University Health System (NUHSRO/2020/R05+5/NUHS-COVID14)
This publication has 102 references indexed in Scilit:
- MalariaThe Lancet, 2014
- Natural stilbenoids: distribution in the plant kingdom and chemotaxonomic interest in VitaceaeNatural Product Reports, 2012
- Deubiquitinating and Interferon Antagonism Activities of Coronavirus Papain-Like ProteasesJournal of Virology, 2010
- Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family CoronaviridaeJournal of Virology, 2010
- Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF-κB SignalingJournal of Virology, 2009
- Mechanism of Action of T-705 against Influenza VirusAntimicrobial Agents and Chemotherapy, 2005
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004
- HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirusBiochemical and Biophysical Research Communications, 2004
- Silencing SARS‐CoV Spike protein expression in cultured cells by RNA interferenceFEBS Letters, 2004
- Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport stepThe Journal of cell biology, 1994